Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (Caelyx): A single-center experience

Oncology

Volumn 73, Issue 3-4, 2008, Pages 277-278

  Rossi, D ^a   Catalano, G ^a  

^a SAN SALVATORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CYTARABINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; PACLITAXEL; PYRIDOXINE;

ADVANCED CANCER; BREAST CANCER; CLINICAL TRIAL; CONTINUOUS INFUSION; HAND FOOT SYNDROME; HUMAN; LETTER; PRIORITY JOURNAL; PROPHYLAXIS; STOMATITIS;

ADMINISTRATION, ORAL; ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; ERYTHEMA; FOOT DERMATOSES; HAND DERMATOSES; HUMANS; PARESTHESIA; POLYETHYLENE GLYCOLS; PYRIDOXINE;

EID: 43049139924     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000127427     Document Type: Letter

References (11)

1. Lokich JJ, Moore C: Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984;101:798-799.
2. O'Brien ME, Wigler N, Inbar M, et al: Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (Caelyx/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440-449.
3. Perez-Lopez ME, Curiel T, Gomez JG, et al: Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer. Anticancer Drugs 2007;18:611-617
4. Cooley T, Henry D, Tonda M, et al: A randomized double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist 2007;12:114-123.
5. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A: Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000;89:1037-1047.
6. Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG: Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumours. Cancer Chemother Pharmacol 1997;39:410-416.
7. Fabian CJ, Molina R, Slavik M, Dhalberg S, Giri S, Stephens R: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990;8:57-63.
8. Vukelja SJ, Keeling JH, Von Hoff D: Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. J Natl Cancer Inst 1993;85:1432.
9. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J: Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 1995;75:2169-2173.
10. Eng C, Mauer AM, Fleming GF, et al: Phase I study of pegylated liposomal doxorubicin, paclitaxel and cisplatin in patients with advanced solid tumors. Ann Oncol 2001;12:1743-1747.
11. Sehouli J, Oskay-Ozcelik G, Kuhne J, et al: Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase II trial. Ann Oncol 2006;17:957-961.